HUTCHMED Receives NMPA’s Conditional Approval for Tazverik to Treat R/R Follicular Lymphoma
Shots:
- China’s NMPA has granted conditional approval to Tazverik for the treatment of adults with r/r follicular lymphoma harbouring EZH2 mutation who had previously received ≥2 systemic therapies
- Approval was based on P-II bridging trial in China & Epizyme-led trials outside of China, where the P-II trial assessed ORR (1EP), with 2EPs incl. DoR, PFS, OS, safety, & PK in R/R FL pts with EZH2 mutations
- Tazverik is being evaluated in ongoing P-Ib/III (SYMPHONY-1) trial in combination with rituximab & lenalidomide (R²) in R/R FL pts who had previously received ≥1 prior therapy; SYMPHONY-1 would be sponsored by Epizyme, with HUTCHMED leading it in China
Ref: HUTCHMED | Image: HUTCHMED
Related News:- Innovent and HUTCHMED Report P-II/III (FRUSICA-2) Trial Data of Sintilimab + Fruquintinib for Metastatic Renal Cell Carcinoma (RCC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
